<SEC-DOCUMENT>0001193125-24-079032.txt : 20240328
<SEC-HEADER>0001193125-24-079032.hdr.sgml : 20240328
<ACCEPTANCE-DATETIME>20240327182525
ACCESSION NUMBER:		0001193125-24-079032
CONFORMED SUBMISSION TYPE:	FWP
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20240328
DATE AS OF CHANGE:		20240327

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Stoke Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001623526
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				471144582
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		FWP
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	333-265107
		FILM NUMBER:		24792492

	BUSINESS ADDRESS:	
		STREET 1:		45 WIGGINS AVENUE
		CITY:			BEDFORD
		STATE:			MA
		ZIP:			01730
		BUSINESS PHONE:		781-430-8200

	MAIL ADDRESS:	
		STREET 1:		45 WIGGINS AVENUE
		CITY:			BEDFORD
		STATE:			MA
		ZIP:			01730

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ASOthera Pharmaceuticals, Inc.
		DATE OF NAME CHANGE:	20141028

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Stoke Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001623526
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				471144582
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		FWP

	BUSINESS ADDRESS:	
		STREET 1:		45 WIGGINS AVENUE
		CITY:			BEDFORD
		STATE:			MA
		ZIP:			01730
		BUSINESS PHONE:		781-430-8200

	MAIL ADDRESS:	
		STREET 1:		45 WIGGINS AVENUE
		CITY:			BEDFORD
		STATE:			MA
		ZIP:			01730

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ASOthera Pharmaceuticals, Inc.
		DATE OF NAME CHANGE:	20141028
</SEC-HEADER>
<DOCUMENT>
<TYPE>FWP
<SEQUENCE>1
<FILENAME>d815145dfwp.htm
<DESCRIPTION>FWP
<TEXT>
<HTML><HEAD>
<TITLE>FWP</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Issuer Free Writing Prospectus </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed Pursuant to Rule 433 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Dated March&nbsp;27, 2024 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Relating to Preliminary Prospectus Supplement Dated March&nbsp;26, 2024 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Registration Statement No.&nbsp;333- 265107 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g815145g0327125247624.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants to Purchase Shares of Common Stock </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This free writing prospectus relates only to the public offering of shares of common stock and <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants to
purchase shares of common stock by Stoke Therapeutics, Inc. and should be read together with the preliminary prospectus supplement dated March&nbsp;26, 2024 (the &#147;Preliminary Prospectus Supplement&#148;), and the accompanying prospectus, in
each case, including the documents incorporated by reference therein. The information in this free writing prospectus updates and, to the extent inconsistent, supersedes the information in the Preliminary Prospectus Supplement. This free writing
prospectus supplements the Preliminary Prospectus Supplement primarily to reflect the addition of certain <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants, and the shares of common stock issuable upon the exercise of such <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants, to the securities being offered by Stoke Therapeutics, Inc. in this offering. Except as otherwise indicated, all information in this free writing prospectus and the Preliminary Prospectus
Supplement assumes no exercise by the underwriters of their option to purchase additional shares of common stock and no exercise of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants included in this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This free writing prospectus is qualified in its entirety by reference to the Preliminary Prospectus Supplement and the accompanying prospectus, in each case,
including the documents incorporated by reference therein. Financial information and other information presented in the Preliminary Prospectus Supplement or incorporated by reference therein is deemed to have changed to the extent affected by the
changes described herein. This free writing prospectus should be read together with the Preliminary Prospectus Supplement and the accompanying prospectus, in each case, including the documents incorporated by reference therein, before making a
decision in connection with an investment in the securities. Capitalized terms used in this free writing prospectus but not defined have the meanings given to them in the Preliminary Prospectus Supplement. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="82%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Common stock offered by us</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$75,000,000 of shares of our common stock.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B><FONT STYLE="white-space:nowrap">Pre-funded&nbsp;warrants</FONT> offered by us</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are also offering, in lieu of common stock, to certain investors who so choose, <FONT STYLE="white-space:nowrap">pre-funded</FONT>
warrants to purchase shares of our common stock. The purchase price of each <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant will equal the price per share at which the shares of our common stock are being sold to the public in this
offering, minus $0.0001, which is the exercise price of each <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant per share. The <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants do not expire, and each
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant will be exercisable at any time after the date of issuance of such <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant, subject to an ownership limitation. See &#147;Description of
pre-funded warrants.&#148; This free writing prospectus and the Preliminary Prospectus Supplement also relate to the offering of the shares of our common stock issuable upon the exercise of such <FONT STYLE="white-space:nowrap">pre-funded</FONT>
warrants.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap">lock-up</FONT> restrictions described
in the Preliminary Prospectus Supplement under &#147;Underwriting&#148; will not apply to issuance of common stock upon the exercise of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants during the
<FONT STYLE="white-space:nowrap">60-day</FONT> period following the date of the final prospectus supplement to be filed in connection with this offering.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Option to purchase additional shares</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">We have granted the underwriters an option to purchase up to an additional $11,250,000 of shares of our common stock at us at the public offering price, less underwriting discounts and commissions, for a period of 30&nbsp;days after
the date of this prospectus supplement. The number of shares subject to the underwriter&#146;s option equals 15% of the total number of shares of common stock we are offering plus the shares of common stock underlying the <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Use of proceeds</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We estimate that our net proceeds from this offering will be approximately $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;million, or
$&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;million if the option to purchase additional shares is exercised in full by the underwriters, after deducting underwriting discounts and commissions and estimated offering expenses payable by us.</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">We intend to use the net proceeds we receive from this offering, together with our
existing cash and cash equivalents, to fund research, clinical and process development and manufacturing of our product candidates, including late-stage development <FONT STYLE="white-space:nowrap">of&nbsp;STK-001&nbsp;and</FONT> further development
<FONT STYLE="white-space:nowrap">of&nbsp;STK-002,&nbsp;developing</FONT> additional product candidates, working capital, capital expenditures and other general corporate purposes. See &#147;Use of proceeds.&#148;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Nasdaq Global Select Market symbol</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Our common stock is listed on The Nasdaq Global Select Market under the symbol &#147;STOK&#148;. We do not intend to list the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants on The Nasdaq Global Select Market or any
other national securities exchange or any recognized trading system. Without an active market, the liquidity of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants will be limited. See &#147;Description of pre-funded
warrants.&#148;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risk factors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If you purchase securities in this offering, you will experience immediate and substantial dilution in the net tangible book value of your shares. In
addition, we may issue additional equity or convertible debt securities in the future, which may result in additional dilution to you. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since the
price per share of our common stock and our <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants being offered is higher than the net tangible book value per share of our common stock, you will suffer dilution with respect to the net tangible
book value of the shares of common stock or the underlying <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants you purchase in this offering. Based on the public offering price of $&#8195;&#8195;&#8195;per share and our net tangible book
value as of December&nbsp;31, 2023, if you purchase shares of common stock in this offering, you will suffer immediate dilution of $&#8195;&#8195;&#8195;per share with respect to the net tangible book value of the common stock. For a more detailed
discussion of the foregoing, see the section titled &#147;Dilution&#148; below. To the extent outstanding stock options are exercised, there will be further dilution to new investors. In addition, we expect to raise additional capital in the future
and if we issue additional shares of common stock or securities convertible or exchangeable for our common stock, our then existing stockholders may experience dilution and the new securities may have rights senior to those of our common stock
offered in this offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>There is no public market for the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants being offered in this
offering. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There is no public trading market for the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants being offered in this offering,
and we do not expect a market to develop. In addition, we do not intend to apply to list the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants on any securities exchange or nationally recognized trading system, including the Nasdaq Global
Select Market. Without an active market, the liquidity of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants will be limited. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Holders
of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants will have no rights as common stockholders until such holders acquire our common stock. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Until holders of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants acquire shares of our common stock upon exercise, holders of the <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants will have no rights with respect to the shares of our common stock underlying <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. Upon exercise of the
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants, the holders will be entitled to exercise the rights of a common stockholder only as to matters for which the record date occurs after the exercise date. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Significant holders or beneficial owners of our common stock may not be permitted to exercise the prefunded warrants that they hold. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A holder of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants will not be entitled to exercise any portion of such
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants which, upon giving effect to such exercise, would cause (i)&nbsp;the aggregate number of shares of our common stock beneficially owned by the holder (together with its affiliates) to exceed
4.99% of the total number of shares of our common stock outstanding immediately after giving effect to the exercise, or (ii)&nbsp;the combined voting power of our securities beneficially owned by such holder (together with its affiliates and other
attribution parties) to exceed 4.99% of the combined voting power of all of our securities then outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants. Such percentage may be increased by the holder of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants to any other percentage not in excess of 19.99% upon at least 61 days&#146;
prior notice from the holder to us. As a result, you may not be able to exercise your <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants for shares of our common stock at a time when it would be financially beneficial for you to do so. In
such circumstance you could seek to sell your <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants to realize value, but you may be unable to do so in the absence of an established trading market for the
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will not receive any meaningful amount of additional funds upon the exercise of the
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant will be exercisable
until it is fully exercised and by means of payment of the nominal cash purchase price upon exercise or by means of a &#147;cashless exercise&#148; according to a formula set forth in the pre-funded warrant. Accordingly, we will not receive any
meaningful additional funds upon the exercise of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we do not maintain a current and effective registration statement relating to the share of common
stock issuable upon exercise of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants, holders will only be able to exercise such <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants on a &#147;cashless basis.&#148; </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we do not maintain a current and effective registration statement relating to the shares of common stock issuable upon exercise of the <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants at the time that holders wish to exercise such <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants, they will only be able to exercise them on a &#147;cashless basis&#148; provided that
an exemption from registration is available. As a result, the number of ordinary shares that holders will receive upon exercise of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants will be fewer than it would have been had such holder
exercised his warrant for cash, and holders may be limited in their ability to immediately sell shares upon exercise subject to volume or other securities law limitations. Further, if an exemption from registration is not available, holders would
not be able to exercise on a cashless basis and would only be able to exercise their <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants for cash if a current and effective registration statement relating to the shares of common stock
issuable upon exercise of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants is available. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Use of proceeds </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We estimate that the net proceeds of this offering, after deducting estimated underwriting discounts and commissions and estimated offering expenses, will be
approximately $&#8195;&#8195;&#8195;&#8195;million, or $&#8195;&#8195;&#8195;&#8195;million if the underwriter&#146;s option to purchase additional shares is exercised in full. We will receive nominal proceeds, if any, from any exercise of <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We currently intend to use the net proceeds of this offering, together with our existing cash and
cash equivalents, to fund research, clinical and process development and manufacturing of our product candidates, including late stage development <FONT STYLE="white-space:nowrap">of&nbsp;STK-001&nbsp;and</FONT> further development <FONT
STYLE="white-space:nowrap">of&nbsp;STK-002,&nbsp;developing</FONT> additional product candidates, working capital, capital expenditures and other general corporate purposes. Additionally, we may use a portion of the net proceeds from this offering
to expand our current business <FONT STYLE="white-space:nowrap">by&nbsp;in-licensing&nbsp;or</FONT> acquiring, as the case may be, commercial products, product candidates, technologies, compounds, other assets or complementary businesses. However,
we have no current commitments or obligations to do so. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The amounts and timing of our actual expenditures will depend on numerous factors, including the
progress of our clinical trials and other development efforts and other factors described under &#147;Risk factors&#148; in this prospectus supplement and the documents incorporated by reference herein, as well as the amount of cash used in our
operations. As a result, our management will have broad discretion over the uses of the net proceeds, if any, we receive in connection with securities offered pursuant to this prospectus supplement and investors will be relying on the judgment of
our management regarding the application of the proceeds. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pending these uses, we intend to invest the net proceeds in short-term or long-term,
investment-grade, interest-bearing securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dilution </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you invest in our common stock or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants in this offering, your ownership interest will be diluted to
the extent of the difference between the public offering price per share of our common stock or prefunded warrant and the as adjusted net tangible book value per share of our common stock after this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our net tangible book value as of December&nbsp;31, 2023 was approximately $159.6&nbsp;million, or $3.48 per share. Net tangible book value per share is
determined by dividing our total tangible assets, less total liabilities, by the number of shares of our common stock outstanding as of December&nbsp;31, 2023. Dilution with respect to net tangible book value per share represents the difference
between the amount per share paid by purchasers of shares of common stock in this offering and the net tangible book value per share of our common stock immediately after this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After giving effect to the sale of (i)&#8195;&#8195;&#8195; shares of our common stock at the public offering price of $&#8195;&#8195;&#8195;per share of
common stock and <FONT STYLE="white-space:nowrap">(ii)&nbsp;pre-funded</FONT> warrants to purchase up to&#8195;&#8195;&#8195;&#8195;shares of our common stock at the public offering price of $&#8195;&#8195;&#8195;&#8195;per <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrant (which equals the public offering price of the common stock at which shares of our common stock are being sold to the public in this offering less the $0.0001 per share exercise price of each such
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant) (excluding shares of common stock issuable upon exercise of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants, any proceeds which may be received upon exercise of the
prefunded warrants or any resulting accounting associated with the exercise of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants) and after deducting estimated underwriting discounts and commissions and estimated offering expenses, our
as adjusted net tangible book value as December&nbsp;31, 2023 would have been approximately $&#8195;&#8195;&#8195;million, or $&#8195;&#8195;&#8195;per share. This represents an immediate increase in net tangible book value of
$&#8195;&#8195;&#8195;per share to existing stockholders and immediate dilution of $&#8195;&#8195;&#8195;per share to investors purchasing our common stock in this offering at the public offering price. The following table illustrates this dilution
on a per share basis: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public offering price per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Historical net tangible book value per share as of December&nbsp;31, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in <FONT STYLE="white-space:nowrap">as-adjusted</FONT> net tangible book value per share
attributable to this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">As-adjusted</FONT> net tangible book value per share after this
offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilution per share to new investors in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If holders of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants exercise were immediately and fully exercised,
the as adjusted net tangible book value per share of our common stock after giving effect to this offering would be $&#8195;per share, and the dilution in net tangible book value per share to investors purchasing common stock in this offering would
be $&#8195;&#8195;&#8195;&#8195;per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the underwriters exercise their option to purchase $11,250,000 of shares in full, the as adjusted net
tangible book value per share of our common stock after giving effect to this offering would be $&#8195;&#8195;&#8195;per share, and the dilution in net tangible book value per share to investors purchasing common stock in this offering would be
$&#8195;&#8195;&#8195;per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing tables and calculations are based on 45,918,233 shares of common stock outstanding as of December&nbsp;31,
2023 and excludes the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">6,478,063 shares of common stock issuable upon exercise of options outstanding as of December&nbsp;31, 2023 with
a weighted average exercise price of $9.64 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,513,102 shares of common stock subject to RSUs granted as of December&nbsp;31, 2023; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">5,411,677&nbsp;shares of common stock reserved and available for future issuance as of December&nbsp;31, 2023
under our equity incentives plans, consisting of (i) 2,767,209 shares of common stock reserved and available for issuance under the 2019 Plan as of December&nbsp;31, 2023; (ii) 1,704,168 shares of common stock reserved for issuance under the ESPP as
of December&nbsp;31, 2023; and (iii) 940,300 shares of common stock reserved and available for issuance under the 2023 Plan; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">shares of our common stock that may be sold from time to time under <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">our&nbsp;at-the-market&nbsp;offering</FONT></FONT> with Cantor Fitzgerald&nbsp;&amp; Co.; 243,362 shares have been sold under
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">this&nbsp;at-the-market&nbsp;offering</FONT></FONT> after December&nbsp;31, 2023 and no shares may be sold under
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">this&nbsp;at-the-market&nbsp;offering</FONT></FONT> until 60 days after the date of this prospectus supplement. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as otherwise indicated, all information in this prospectus supplement assumes no issuance or exercise of outstanding options or RSUs subsequent to
December&nbsp;31, 2023 and no exercise of the underwriter&#146;s option to purchase additional shares of common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the extent that outstanding
options have been or may be exercised, or other shares are issued, investors purchasing our common stock in this offering may experience further dilution. In addition, we may choose to issue additional common stock, or securities convertible into or
exchangeable for common stock, in the future. The issuance of these securities could result in further dilution for investors purchasing our common stock in this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Description of <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following is a brief summary of certain terms and conditions of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants being offered by this
prospectus supplement. The following description is subject in all respects to the provisions contained in the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Form </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants will be issued as individual warrant agreements to investors. The form of <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant will be filed as an exhibit to a Current Report on Form <FONT
STYLE="white-space:nowrap">8-K</FONT> that we expect to file with the SEC in connection with this offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Term </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants do not expire. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exercisability </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants are exercisable at any time on or after their original issuance. The <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants are exercisable, at the option of each holder, in whole or
in part by delivering to us a duly signed exercise notice and by payment in full in immediately available funds for the number of shares of common stock purchased upon such exercise. As an alternative to payment in immediately available funds, the
holder may, in its sole discretion, elect to exercise the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant through a cashless exercise, in which case the holder would receive upon such exercise the net number of shares of common stock
determined according to the formula set forth in the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant. No fractional shares of common stock will be issued in connection with the exercise of a
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant. In lieu of fractional shares, we will pay the holder an amount in cash equal to the fractional amount multiplied by the fair market value of the common stock on the exercise date. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exercise limitations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may not effect the exercise of
any <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant, and a holder will not be entitled to exercise any portion of any <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant that, upon giving effect to such exercise, would cause the
aggregate number of shares of our common stock beneficially owned by the holder (together with its attribution affiliates (as defined below)) to exceed 4.99% of the number of shares of our common stock that would be outstanding immediately after
giving effect to the exercise. However, any holder of a <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant may increase or decrease such percentage to any other percentage not in excess of 19.99% upon at least 61 days&#146; prior notice from
the holder to us. For purposes of the foregoing, &#147;attribution affiliates&#148; means, collectively, the following persons and entities with respect to any holder: (i)&nbsp;its direct or indirect affiliates, (ii)&nbsp;any person acting or who
could be deemed to be acting as a Section&nbsp;13(d) &#147;group&#148; together with the holder or any attribution parties and (iii)&nbsp;any other persons whose beneficial ownership of our common stock would or could be aggregated with the holder
and/or any other attribution parties for purposes of Section&nbsp;13(d) or Section&nbsp;16 of the Securities Exchange Act of 1934, as amended. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exercise price </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The exercise price per whole share of our
common stock purchasable upon the exercise of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants is $0.0001 per share of common stock. The exercise price of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants and the number
of shares of our common stock issuable upon exercise of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants is subject to appropriate adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations,
reclassifications or similar events affecting our common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transferability </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to applicable laws, the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants may be offered for sale, sold, transferred or assigned without our
consent. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exchange listing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There is no established
public trading market for the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants, and we do not expect a market to develop. In addition, We do not plan on applying to list the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants on
the Nasdaq Global Select Market, any other national securities exchange or any other nationally recognized trading system. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Fundamental transactions
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event of a fundamental transaction, as described in the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants and generally including any
reorganization, recapitalization or reclassification of our common stock, the sale, transfer or other disposition of all or substantially all of our properties or assets, our consolidation or merger with or into another person, the acquisition of
more than 50% of our outstanding common stock, or any person or group becoming the beneficial owner of more than 50% of the voting power represented by our outstanding common stock, the holders of the
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants will be entitled to receive upon exercise of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants the kind and amount of securities, cash or other property that the holders would
have received had they exercised the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants immediately prior to such fundamental transaction without regard to any limitations on exercise contained in the
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No rights as a stockholder </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except for the right to participate in certain dividends and distributions and as otherwise provided in the <FONT STYLE="white-space:nowrap">pre-funded</FONT>
warrants or by virtue of a holder&#146;s ownership of shares of our common stock, the holder of a <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant does not have the rights or privileges of a holder of our common stock, including any voting
rights, until the holder exercises the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Underwriting </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriters will purchase the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants pursuant to the underwriting agreement described in the
Preliminary Prospectus Supplement on terms generally consistent with those applicable to the shares of common stock being sold in the offering. The per share underwriting discounts and commissions for the
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants will be equal to the per share underwriting discounts and commissions on the shares of common stock sold in the offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Material U.S. federal income tax consequences </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although it is not entirely free from doubt, because the exercise price of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants is a nominal amount,
we expect to treat the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants as our common stock for U.S. federal income tax purposes. Assuming this characterization applies, a <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant should
be treated as a share of our common stock for U.S. federal income tax purposes and a holder of <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants should generally be taxed in the same manner as a holder of such common stock, as described in
the Preliminary Prospectus Supplement under &#147;Material U.S. federal income tax considerations to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders.&#148; Accordingly, no gain or loss should be recognized (other than with respect to cash
paid in lieu of a fractional share) upon the exercise of a <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant and, upon exercise, the holding period of a <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant should carry over to the
common stock received. Similarly, the tax basis of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant should carry over to the share received upon exercise, increased by the exercise price per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our characterization is not binding on the IRS, and the IRS may treat our <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants as warrants to acquire
our common stock. In that case, the amount and character of your gain with respect to an investment in our <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants could change. Accordingly, each holder should consult his, her or its tax advisor
regarding the risks associated with the acquisition of <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants pursuant to this offering based on your particular facts and circumstances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A holder of a <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant may, in some circumstances, be deemed to have received a distribution subject to U.S.
federal income tax as a result of an adjustment or the <FONT STYLE="white-space:nowrap">non-occurrence</FONT> of an adjustment to the exercise price or number of shares of common stock issuable upon exercise of the
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant. You should consult your tax advisor regarding the proper treatment of any adjustments to the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additional conforming changes are hereby made to the Preliminary Prospectus Supplement to reflect the changes described in this free writing prospectus. All
terms of the Preliminary Prospectus Supplement applicable to our shares of our common stock will be applicable to the shares of common stock underlying the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants upon issuance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stoke Therapeutics, Inc. has filed a registration statement (including a preliminary prospectus supplement dated March</B><B></B><B>&nbsp;26, 2024 and the
accompanying base prospectus) with the Securities and Exchange Commission (the &#147;SEC&#148;) for the offering to which this communication relates, declared effective by the SEC on May</B><B></B><B>&nbsp;31, 2022. Before you invest, you should
read the preliminary prospectus supplement and the accompanying base prospectus and other documents Stoke Therapeutics, Inc. has filed with the SEC for more complete information about Stoke Therapeutics, Inc. and the offering. You may get these
documents for free by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, copies may be obtained by contacting: J.P. Morgan Securities LLC, c/o: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, by
telephone at <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">866-803-9204</FONT></FONT> or by email at</B><B></B><B>&nbsp;<U><FONT STYLE="white-space:nowrap">prospectus-eq_fi@jpmchase.com</FONT></U></B>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g815145g0327125247624.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g815145g0327125247624.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !] 08# 2(  A$! Q$!_\0
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M+_L.XE6.YC<M$&.-ZGT]Z /4J2C-+0!G1:%IL.K2ZG':1K>2 !I<<UH8I:*
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M_=VL!R?]IN /YT >Y2_ZE_\ =-?-ND->KXW4Z<J->?:'\D2=-W-?24O^I?\
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M+WQ]XX#E#F>0,^.1'&/_ *U?14,:PPI$@PJ*% ]A0 ^BBB@#YX\3?\E2NO\
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MM_\ (E/_ -=TH R_@O\ \@34?^NZ_P J]/KR3X1ZOIVGZ1?)>WL%NS3 J)9
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=P0,L,#@D=<'C-%;,%O#:Q"*"-8XQT51@44 ?_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
